UroGen Pharma Ltd
URGN
40.70
-0.73
-1.76%
UroGen Pharma Ltd
US · URGN
#2773 by market cap
Listed 2017
40.70
-0.73
-1.76%
Live - 5344 symbols - heartbeat 467s ago
· 2026-10-08 05:49
Pre-market
40.90
+0.49%
After-hours
40.50
-0.49%
- Market cap
- 1.99B
- P/E (TTM)i
- -20.66
- P/Bi
- -15.02
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on URGN?
Anonymous reader poll. Unscientific, not investment advice.
About UroGen Pharma Ltd
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
- Founded
- 2004
- CEO
- Ms. Elizabeth Barrett
- Employees
- 291
- Headquarters
- Princeton, New Jersey, United States of America
- Fiscal year end
- 12-31
- Website
- urogen.com
Company profile
- Exchange
- US
- Symbol
- URGN
- Market-cap rank
- #2773
- Listing date
- 2017-05-04
- Market cap
- 1.99B
- Float cap
- 1.77B
- Shares out
- 48.88M
- Float shares
- 43.41M
Sectors & themes
Quote time 2026-10-08 05:49:07 · For reference only, not investment advice and not tailored to your situation.